The 14 analysts offering 12-month price forecasts for Mirati Therapeutics Inc have a median target of 109.50, with a high estimate of 195.00 and a low estimate of 80.00. The median estimate represents a +31.96% increase from the last price of 82.98.
The current consensus among 16 polled investment analysts is to Buy stock in Mirati Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$3.50
Reporting Date Nov 07
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.